CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907 · cited 1×
“perfusion injury (53)dconverge on insufficient mitochondrial energy output and contractile failure as the basic mechanism.”
BackgroundESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048 · cited 1×
“and functional manifestation (reduced or preserved ejection fraction) (51).”
Background
Cited by
Items 401–500 of 1,000
Acid-base and electrolyte disorders associated with the use of antidiabetic drugs
Filippatos, T. D., Tzavella, E., Rizos, C. V., Elisaf, M., & Liamis, G. L. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361400 · Cited by 33
SGLT2 inhibitors and protection against pancreatic beta cell failure
Asahara, S., & Ogawa, W. (2018) · Diabetology International · doi:10.1007/s13340-018-0374-y · Cited by 27
ナトリウム・グルコース共輸送体2(SGLT2)阻害薬カナグリフロジンは非糖尿病マウスの遅筋および速筋に異なる影響を及ぼす
Otsuka, H. (2023) · Institutional Repositories DataBase (IRDB) · Cited by 27
Stachteas, P., Nasoufidou, A., Karagiannidis, E., Patoulias, D., Karakasis, P., Alexiou, S., Samaras, A., Zormpas, G., Stavropoulos, G., Tsalikakis, D., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185408 · Cited by 27
“In a recent study, SGLT2is demonstrated the ability to increase mitochondrial biogenesis partially due to metabolic alterations like ketone body formation [26], and empagliflozin was observed to potentially restore mitochondrial dysfunction [27].”
BackgroundTreating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus
Trang, A., & Aguilar, D. A. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0371-7 · Cited by 28
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26
Cardio-renal protection with empagliflozin
MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.10.36 · Cited by 27
Kalra, S., Ghosh, S. K., Aamir, A., Ahmed, M. T., Amin, M. F., Bajaj, S., Baruah, M., Bulugahapitiya, U., Das, A., Giri, M., et al. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196029 · Cited by 31
Tochiya, M., Makino, H., Tamanaha, T., Matsuo, M., Hishida, A., Koezuka, R., Ohata, Y., Tomita, T., Son, C., Miyamoto, Y., et al. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13122 · Cited by 27
Cardioprotective effects of short-term empagliflozin treatment in db/db mice
Radlinger, B., Hornsteiner, F., Folie, S., Salvenmoser, W., Haubner, B. J., Schuetz, T., Haas, S., Ress, C., Adolph, T. E., Salzmann, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76698-8 · Cited by 27
Guo, L., Du, Y., Li, H., He, T., Yao, L., Yang, G., & Yang, X. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156144 · Cited by 34
Papazafiropoulou, A. K., Georgopoulos, M., & Katsilambros, N. L. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.112475 · Cited by 27
Wichaiyo, S., & Saengklub, N. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10220-2 · Cited by 26
Shiraki, A., Oyama, J., Shimizu, T., Nakajima, T., Yokota, T., & Node, K. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175194 · Cited by 25
Osonoi, T., Gouda, M., Kubo, M., Arakawa, K., Hashimoto, T., & Abe, M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0169 · Cited by 26
The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia
Loutradis, C., Papadopoulou, E., Angeloudi, E., Karagiannis, A. I., & Sarafidis, P. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191029111713 · Cited by 25
Hattori, Y. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10065-7 · Cited by 25
Kanbay, M., Al-Shiab, R., Shah, E., Özbek, L., Güldan, M., Ortíz, A., & Fouque, D. P. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf351 · Cited by 28
“SGLT-2is promote a metabolic transition toward ketogen-esis by enhancing hepatic lipid oxidation and increasing circulating ketone bodies, which serve as efficient energy substrates for the kidneys and heart [30 ].”
Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
Voorrips, S. N., Saucedo‐Orozco, H., Sánchez-Aguilera, P., de Boer, R. A., van der Meer, P., & Westenbrink, B. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158631 · Cited by 26
“First of all, the upregulation of ketone bodies has been hypothesized to be an important contributor to the cardioprotective effect of SGLT2 inhibitors [48,199].”
BackgroundRenal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
Vargas-Delgado, A. P., Herrera, E. C. A., Mite, C. J. T., Cedeño, P. D., Loon, M. C. V., & Badimón, J. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044144 · Cited by 27
Sanz, R. L., Inserra, F., Menéndez, S. G., Mazzei, L. J., Ferder, L., & Manucha, W. A. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01240-w · Cited by 26
Kochanowska, A., Rusztyn, P., Szczerkowska, K., Surma, S., Gąsecka, A., Jaguszewski, M. J., Szarpak, Ł., & Filipiak, K. J. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10070268 · Cited by 29
Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome
Lempesis, I. G., Apple, S. J., Duarte, G., Palaiodimos, L., Kalaitzopoulos, D. R., Dalamaga, Μ., & Kokkinidis, D. G. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3682 · Cited by 25
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Vercalsteren, E., Karampatsi, D., Buizza, C., Nyström, T., Klein, T., Paul, G., Patrone, C., & Darsalia, V. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02174-6 · Cited by 25
“The increased ketone-produc-tion upon SGLT2i-treatment is modest [53, 76], suggesting that the effects of Empagliflozin on serum BHB might have been masked by the pronounced tMCAO-induced weight loss inherent to our T2D/stroke model.”
ResultTargeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction
Selvaraj, S., Patel, S., Sauer, A. J., McGarrah, R. W., Jones, P. G., Kwee, L. C., Windsor, S. L., Ilkayeva, O., Muehlbauer, M. J., Newgard, C. B., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.02.018 · Cited by 28
SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art
Aristizábal-Colorado, D., Ocampo-Posada, M., Martínez, W. A. R., Corredor-Rengifo, D., Rico-Fontalvo, J. E., Gómez‐Mesa, J. E., Ossman, J. J. D., & Abreu-Lomba, A. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00673-1 · Cited by 25
Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258055 · Cited by 24
Savonitto, S., Morici, N., Nozza, A., Cosentino, F., Filardi, P. P., Murena, E., Morocutti, G., Ferri, M., Cavallini, C., Eijkemans, M. J. C., et al. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117735493 · Cited by 26
Lee, S. J., Lee, K. H., Oh, H. G., Seo, H. J., Jeong, S. J., & Kim, C. H. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.4.254 · Cited by 24
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Brito, D. A., Bettencourt, P., Carvalho, D. M., Ferreira, J., Fontes‐Carvalho, R., Franco, F., Moura, B., Silva‐Cardoso, J., de Melo, R. T., & Fonseca, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06973-3 · Cited by 27
Sampani, E., Sarafidis, P. A., & Papagianni, A. A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1764532 · Cited by 27
Papaetis, G. S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105314 · Cited by 25
Kario, K., Weber, M. A., & Ferrannini, E. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13229 · Cited by 24
Self-citationSodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting
Peacock, S. C., & Lovshin, J. A. (2017) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-017-1019-5 · Cited by 24
Tian, L., Cai, Y., Zheng, H., Ai, S., Zhou, M., Luo, Q., Tang, J., Liu, W., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.691878 · Cited by 23
The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy
Su, S., Ji, X., Li, T., Teng, Y., Wang, B., Han, X., & Zhao, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1291450 · Cited by 26
Luong, T. V., Pedersen, M. G. B., Abild, C. B., Lauritsen, K. M., Kjærulff, M. L. G., Møller, N., Gormsen, L. C., & Søndergaard, E. (2024) · Diabetes · doi:10.2337/db24-0162 · Cited by 25
New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
Hung, C., & Lu, L. (2024) · Neurology International · doi:10.3390/neurolint16060124 · Cited by 24
Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., et al. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115964 · Cited by 24
Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
Zeng, Q., Zhou, Q., Liu, W., Wang, Y., Xu, X., & Xu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.636152 · Cited by 26
Baker, H. E., Tune, J. D., Mather, K. J., Blaettner, B. S., Clark, H. E., Li, F., Li, X., Kowala, M. C., Fliegel, L., & Goodwill, A. G. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.054 · Cited by 25
Unmasking and aggravation of polycythemia vera by canagliflozin
Das, L., Bhansali, A. K., & Walia, R. (2018) · Diabetic Medicine · doi:10.1111/dme.13706 · Cited by 25
GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30263-7 · Cited by 22
Bocchi, E. A., Biolo, A., Moura, L. Z., de Figueiredo, J. A., Montenegro, C. E. L., & de Albuquerque, D. C. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210031 · Cited by 39
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1193-3793 · Cited by 33
Wee, C. F., Teo, Y. H., Teo, Y. N., Syn, N. L. X., See, R. M., Leong, S., Yip, A. S. Y., Ong, Z. X., Lee, C., Chan, M. Y., et al. (2022) · Journal of Cardiovascular Imaging · doi:10.4250/jcvi.2021.0159 · Cited by 22
Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review
Wu, J., Liu, Y., Wei, X., Zhang, X., Ye, Y., Li, W., & Su, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.915455 · Cited by 24
Ketogenic diet modulates cardiac metabolic dysregulation in streptozocin-induced diabetic rats
Trang, N. N., Lee, T., Kao, Y., Chao, T., Lee, T.-I., & Chen, Y. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109161 · Cited by 22
Chiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
Giaccari, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13814 · Cited by 23
Harnessing the Benefits of Endogenous Hydrogen Sulfide to Reduce Cardiovascular Disease
Casin, K. M., & Calvert, J. W. (2021) · Antioxidants · doi:10.3390/antiox10030383 · Cited by 22
Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure
Verbrugge, F. H. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0340-1 · Cited by 23
Why the diabetic heart is energy inefficient: a ketogenesis and ketolysis perspective
Mishra, P. K. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00260.2021 · Cited by 22
Loutradis, C., Papadopoulou, E., Theodorakopoulou, M. P., Karagiannis, A. I., & Sarafidis, P. A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0514 · Cited by 23
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 23
Janjusevic, M., Fluca, A. L., Gagno, G., Pierri, A., Padoan, L., Sorrentino, A., Beltrami, A. P., Sinagra, G., & Aleksova, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042336 · Cited by 24
McLarnon, S. R., Patel, B., Irsik, D. L., Sun, J., Ocasio, H., Crislip, G. R., Jin, C., Chen, J., Baban, B., Polichnowski, A. J., et al. (2018) · Clinical Science · doi:10.1042/cs20171630 · Cited by 22
Kanbay, M., Yerlikaya, A., Sag, A. A., Ortíz, A., Kuwabara, M., Covic, A. C., Więcek, A., Stenvinkel, P., & Afşar, B. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz106 · Cited by 22
Hattori, Y. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09921-3 · Cited by 26
Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Kuchay, M. S., Farooqui, K. J., Mishra, S. K., & Mithal, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_479 · Cited by 22
Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis
Cai, R., Xu, Y., & Su, Q. (2021) · Cardiology Research and Practice · doi:10.1155/2021/6657380 · Cited by 22
Rasmussen, D. G. K., Hansen, M. K., Blair, J., Jatkoe, T. A., Neal, B. C., Karsdal, M. A., & Genovese, F. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01666-7 · Cited by 22
Kostrzewska, P., Kuca, P., Witek, P., Małyszko, J., Madetko‐Alster, N., & Alster, P. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00832-9 · Cited by 23
Luo, W., He, M., Luo, Q., & Li, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1066822 · Cited by 20
Aziz, F., Tripolt, N. J., Pferschy, P. N., Scharnagl, H., Abdellatif, M., Oulhaj, A., Benedikt, M., Kolesnik, E., von Lewinski, D., & Sourij, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02221-2 · Cited by 20
Lipotoxicity, Nutrient-Sensing Signals, and Autophagy in Diabetic Nephropathy
Kume, S., & Maegawa, H. (2020) · JMA Journal · doi:10.31662/jmaj.2020-0005 · Cited by 24
Pan, X., Xu, S., Li, J., & Tong, N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.599355 · Cited by 21
CrossTalk proposal: Ketone bodies are an important metabolic fuel for the heart
Karwi, Q. G., & Lopaschuk, G. D. (2021) · The Journal of Physiology · doi:10.1113/jp281004 · Cited by 21
“In this context, it has been widely proposed that ketone bodies could serve as a ‘thrifty fuel’ for the failing heart (Ferrannini et al. 2016).”
BackgroundKashiwagi, Y., Nagoshi, T., Inoue, Y., Tanaka, Y., Takahashi, H., Oi, Y., Kimura, H., Minai, K., & Yoshimura, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-86126-0 · Cited by 22
Blood glucose regulation in context of infection
Wensveen, F. M., Šestan, M., Wensveen, T. T., & Polić, B. (2021) · Vitamins and hormones · doi:10.1016/bs.vh.2021.06.009 · Cited by 22
MacDonald, T. L., Pattamaprapanont, P., Cooney, E. M., Nava, R. C., Mitri, J., Hafida, S., & Lessard, S. J. (2022) · Diabetes · doi:10.2337/db21-0934 · Cited by 21
Suhrs, H. E., Nilsson, M. S. D., Bove, K. B., Zander, M., & Prescott, E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263481 · Cited by 20
Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice
Abdurrachim, D., Manders, E., Nicolay, K., Mayoux, E., & Prompers, J. J. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy246 · Cited by 20
Self-citationKetone Body Infusion Increases Circulating Erythropoietin and Bone Marrow Glucose Uptake
Lauritsen, K. M., Søndergaard, E., Svart, M. V., Møller, N., & Gormsen, L. C. (2018) · Diabetes Care · doi:10.2337/dc18-1421 · Cited by 20
Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies
Muñoz‐Córdova, F., Hernández-Fuentes, C. P., López‐Crisosto, C., Troncoso, M. F., Calle, X., Guerrero‐Moncayo, A., Gabrielli, L., Chiong, M., Castro, P., & Lavandero, S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.707336 · Cited by 21
Luong, T. V., Pedersen, M. G. B., Abild, C. B., Cunnane, S. C., Croteau, É., Lauritsen, K. M., Kjærulff, M. L. G., Tolbod, L. P., Møller, N., Søndergaard, E., et al. (2024) · Obesity · doi:10.1002/oby.23967 · Cited by 19
“However, even if all fatty acids were replaced by ketone bodies as a source of myocardial energy, this would only reduce oxygen consumption by (cid:1) 5% as calculated by the equations given as the foundation for the thrifty substrate hypothesis [6].”
BackgroundInfluentialLiu, J., Liu, S., Gurung, R. L., Chan, C., Ang, K., Tang, W. E., Subramaniam, T., Sum, C. F., & Lim, S. C. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00321 · Cited by 21
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 20
Zhang, Q., Li, G., Zhong, Y., Wang, J., Wang, A., Zhou, X., & Mao, X. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320974833 · Cited by 19
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
Hojná, S., Rauchová, H., Malínská, H., Marková, I., Hüttl, M., Papoušek, F., Behuliak, M., Miklánková, D., Vaňourková, Z., Neckář, J., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112246 · Cited by 19
Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6/J mice
Xie, B., Ramirez, W., Mills, A. M., Huckestein, B. R., Anderson, M., Pangburn, M. M., Lang, E. Y., Mullett, S. J., Chuan, B. W., Guo, L., et al. (2022) · Current Research in Physiology · doi:10.1016/j.crphys.2022.05.003 · Cited by 19
“Metabolic flexibility and cardiac substrate selection are regulated by multiple factors including the expression and activity of key mediators of substrate selection, such as PDH and CPT1 (Fillmore et al., 2014).”
BackgroundFerrannini, E., Baldi, S., Scozzaro, T., Tsimihodimos, V., Tesfaye, F., Shaw, W. C., Rosenthal, N. R., Figtree, G. A., Neal, B. C., Mahaffey, K. W., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2398 · Cited by 20
Self-citationDifferential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
Papakitsou, I., Vougiouklakis, G., Elisaf, M., & Filippatos, T. D. (2019) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s172353 · Cited by 29
Ibrahim, N. E., & Januzzi, J. L. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa277 · Cited by 19
Wang, Y., Yao, M., Wang, J., Liu, H., Zhang, X., Zhao, L., Hu, X., Guan, H., & Lyu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.818537 · Cited by 18
Monteiro, P. F., Aguíar, C., Matos, P. L. P., Silva‐Nunes, J., Birne, R., Branco, P. Q., Calado, J., Melo, M., & Polónia, J. J. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.02.015 · Cited by 19
Li, L., Hua, C., Liu, X., Wang, Y., Zhao, L., Zhang, Y., Wang, L., Su, P., Yang, M.-F., & Xie, B. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001453 · Cited by 18
d’Aiello, A., Bonanni, A., Vinci, R., Pedicino, D., Severino, A., Vita, A. D., Filomia, S., Brecciaroli, M., & Liuzzo, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108643 · Cited by 19
Cancer and Cardiovascular Disease: The Conjoined Twins
Zmaili, M. A., Alzubi, J. M., Alkhayyat, M. M., Albakri, A. A., Alkhalaileh, F., Longinow, J., & Moudgil, R. (2024) · Cancers · doi:10.3390/cancers16081450 · Cited by 21
“In addition, SGLT2 inhibition was found to shift metabolism toward more lipid oxidation and ketone production along with reduced glucose oxidation [224,225]. other potential mechanisms for cardiovascular benefits of SGLT2 inhibitors include enhanced natriuresis, reduction in plasma volume and blood…”
BackgroundRudzki, G., Knop-Chodyła, K., Piasecka, Z., Kochanowska-Mazurek, A., Głaz, A., Wesołek, E., & Woźniak, M. M. (2024) · Pharmaceuticals · doi:10.3390/ph17080987 · Cited by 20
“In kidney transplant patients, such a change in metabolism and its increase at the mitochondrial level may improve the condition of the transplanted organ and have a beneficial effect on immune cells, especially T lymphocytes [65,66].”
BackgroundMolecular Basis of Cardiomyopathies in Type 2 Diabetes
Giardinelli, S., Meliota, G., Mentino, D., D’Amato, G., & Faienza, M. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158280 · Cited by 18
“In this condition, the heart uses more beta-hydroxybutyrate—which is a ketone—than usual to produce energy instead of fatty acids [161].”
BackgroundAbdelgadir, E., Rashid, F., Bashier, A. M., & Ali, R. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3467w · Cited by 21
SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials
Jia, X., Mehta, P. B., Ye, Y., Alam, M., Birnbaum, Y., & Bajaj, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1038-9 · Cited by 19
New Agents for the Treatment of Type 2 Diabetes
Libianto, R., & Ekinci, E. I. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.007 · Cited by 19
Matsubayashi, Y., Yoshida, A., Suganami, H., OSAWA, T., Furukawa, K., Suzuki, H., Fujihara, K., Tanaka, S., Kaku, K., & Sone, H. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13980 · Cited by 18
“Recent studies suggested that BHB might be cardioprotective because BHB is freely taken up by the heart and is oxidized in priority to FFA and that in the myocardium, the use of ketone bodies might be energy efficient through improving oxygen consumption.(36) As mentioned above, in general, decreases in hepatic insuli…”
BackgroundThe Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
Liu, J., Tian, J., Sodhi, K., & Shapiro, J. I. (2021) · The Journal of Membrane Biology · doi:10.1007/s00232-021-00192-z · Cited by 19
Pistelli, L., Parisi, F., Correale, M., Cocuzza, F., Campanella, F., Ferrari, T. D., Crea, P., Sarro, R. D., Cognata, O. M. L., Ceratti, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010379 · Cited by 22
Lehrke, M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.023 · Cited by 18
the EMPA-ICD investigators, Fujiki, S., Iijima, K., Okabe, M., Niwano, S., Tsujita, K., Naito, S., Andò, K., KUSANO, K. F., Kato, R., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00924-9 · Cited by 17
Metadata
- Authors
- Ferrannini, E., Mark, M., & Mayoux, E.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-11
- Volume
- 39
- Issue
- 7
- Pages
- 1108-1114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2412800896
- Cited by
- 975
- References
- 77
- Citations by year
- 2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
- FWCI
- 125.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.